Diego A. Díaz García/X
Jun 28, 2025, 23:31
Diego A. Díaz García: Targeted Therapies in Metastatic NSCLC
Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared on X:
“Next-gen targeted therapies are reshaping frontline treatment in metastatic NSCLC.
Improved CNS penetration
Better resistance profiles
Enhanced selectivity = more efficacy, less toxicity
The future? Smarter combinations and biomarker-driven strategies.”
Title: Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Authors: Sarah Waliany, Jessica J. Lin, Justin F. Gainor
Read the Full Article.
More posts featuring Diego Díaz García.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 10:25
Jul 3, 2025, 10:24
Jul 3, 2025, 10:16
Jul 3, 2025, 10:15
Jul 3, 2025, 10:04
Jul 3, 2025, 09:50